drugset / Trial / NCT00700063

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00700063

Phase 2 Completed 265 enrolled Peplin
RandomizedParallel-groupTriple-blindTreatment

Summary

This Phase IIb study is designed to assess the safety and efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel when applied to an area of skin, containing 4-8 AK lesions on the face or scalp.

Timeline

Start
2008-06
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ingenol mebutate Small molecule 0.005 % Topical
Subject ingenol mebutate Small molecule 0.01 % Topical
Subject ingenol mebutate Small molecule 0.015 % Topical

Indications